Renub

    Pediatric Vaccines Market, Share, Global Forecast 2022-2027, Industry Trends, Growth, Size, Impact of COVID-19, Company Analysis

    Excel: 12 Hours
    PDF: 24 Hours
    Jan 2022
    Pages: 150

     Get Free Customization in This Report

    Global Pediatric Vaccines Market is expected to reach USD 62 Billion in 2027. In this huge market of vaccines Pediatric Vaccines for Coronavirus account for a significant market share. Over the years, Pediatric vaccination has made a tremendous public health success story. The lives of billions of children have been saved, and millions have the chance of a longer, healthier life, a more significant opportunity to learn, play, read and write, and move around freely without suffering. Besides, in the 21st century, the development, licensing, and implementation of Pediatric vaccines as part of large, systematic immunization programs have also addressed global health inequities. Therefore, imagining a world without vaccines would be life-threatening, with diseases presenting daily risk.


    Impact of COVID-19 on Global Pediatric Vaccines Market

    With the emergence of the SARS-CoV-2 virus in December 2019 and its potential for global dissemination to cause COVID-19 disease was realized, there was an urgent need to develop vaccines at an unprecedented rate and scale for the particular pandemic. Hence, amidst the pandemic, the global market for Pediatric vaccines declined in 2020 as most of the healthcares personal were busy in COVID-19 management.

     

    pediatric vaccines market


    However, the Pediatric vaccines market size has shown tremendous growth for the year 2021. All thanks to the COVID-19 vaccines approval for children in few western countries. Furthermore, as we appreciate and quantify the health, economic and social benefits of Pediatric vaccines and immunization programs to individuals and society. We endeavour to see the Global Pediatric Vaccine Industry to register a CAGR of 4.4% during the forecast period of 2021-2027.


    Numbers of Vaccinated Pediatric (Infants) Remains Variable

    At the same time, access to Pediatric vaccines that prevent life-threatening infectious diseases remains variable to all infants around the world. Further, to eradicate such problems, numerous individuals and agencies are working hard to address them globally. Recently, the development of safe and efficacious vaccination against diseases that cause substantial morbidity and mortality has been a significant scientific advance. Vaccination, sanitation, and clean drinking water are public health interventions that are undeniably responsible for improved infant health outcomes globally.


    For instance, agencies including the United Nations Children's Fund (UNICEF), World Health Organization (WHO), Gavi, The Bill & Melinda Gates Foundation, the Vaccine Alliance, and the Coalition for Epidemic Preparedness Initiative (CEPI), with their multiple funding streams have been instrumental in expanding vaccine benefits to all.


    Worldwide Pediatric Vaccines Market Size was US$ 47.8 Billion for 2021

    The global pediatric vaccines market is robust and has successfully reached enormous potential. Hence, pediatric vaccines are among tremendous advances in global health and development. Besides, pediatric vaccines have safely reduced the scourge of diseases like Influenza, MMR, Pneumococcal, Meningococcal, Hepatitis, DTaP, Hib (Haemophilus Influenza Type B), Combos (Combination Vaccines), Polio, Rotavirus and Varicella, helping children grow up healthy and happy. Remarkably, with immunization efforts worldwide, children can walk, play, dance and learn. Today, vaccines are expected to be one of the most cost-effective means of advancing global welfare.


    Major Players in Global Pediatric Vaccines Market

    The Pediatric vaccines market consists of several major players, including GlaxoSmithKline, Merck & Co, Sanofi Pasteur's, Pfizer, Inc. and Thoracic Aortic Aneurysm (TAA)CSL Limited. Notwithstanding, the key players of pediatric vaccines are broad and far-reaching, though not consistently quantifiable, analyzed or communicated. However, an increasing appreciation for vaccines' economic and social effects is being included in the development of the new vaccine, potentially realizing a more significant benefit to society and resulting in broader implementation by the companies.


    Renub Research latest report “Pediatric Vaccines Market, Global Forecast By Disease Wise (Influenza, MMR, Pneumococcal, Meningococcal, Hepatitis, DTaP, Hib (Haemophilus Influenza Type B), Combos (Combination Vaccines), Polio, Rotavirus and Varicella), Crop (Influenza, MMR, Pneumococcal, Meningococcal, Hepatitis, DTaP, Hib (Haemophilus Influenza Type B), Combos (Combination Vaccines), Polio, Rotavirus and Varicella), Products and Pipeline (GSK Vaccine Product Pipeline, Merck Vaccine Product Pipeline, Sanofi Vaccine Product Pipeline and Pfizer Vaccine Product Pipeline), Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa), Key Players Sales (GlaxoSmithKline, Merck & Co, Sanofi Pasteur's, Pfizer, Inc. and Thoracic Aortic Aneurysm (TAA)CSL Limited)” provides a detailed analysis of Pediatric Vaccines Industry.

     

    global pediatric vaccines market


    Disease wise – Pediatric (Infants) Vaccines Market have been covered from 12 viewpoints:

    1.    Coronavirus (COVID-19)
    2.    Influenza
    3.    MMR (Measles, Mumps, and Rubella Vaccine)
    4.    Pneumococcal
    5.    Meningococcal
    6.    Hepatitis
    7.    DTaP
    8.    Haemophilus Influenzae Type B (HIB)
    9.    Combos (Combination)
    10.    Polio
    11.    Rotavirus
    12.    Varicella


    Disease wise – Numbers of Vaccinated Pediatric (Infants) have been covered from 12 viewpoints:

    1.    Coronavirus (COVID-19)
    2.    Influenza
    3.    MMR (Measles, Mumps, and Rubella Vaccine)
    4.    Pneumococcal
    5.    Meningococcal
    6.    Hepatitis
    7.    DTaP
    8.    Haemophilus Influenzae Type B (HIB)
    9.    Combos (Combination)
    10.    Polio
    11.    Rotavirus
    12.    Varicella


    By Regions – Pediatric (Infants) Vaccines Market and Number have been covered from 5 viewpoints:

    1.    North America
    2.    Europe
    3.    Asia Pacific
    4.    Latin America
    5.    Middle East and Africa


    Vaccines – Products and Pipeline have been covered from 4 viewpoints:

    1.    GSK Vaccine Product Pipeline
    2.    Merck Vaccine Product Pipeline
    3.    Sanofi Vaccine Product Pipeline
    4.    Pfizer Vaccine Product Pipeline


    Company Insight:

    •    Overview
    •    Recent Development
    •    Sales Analysis


    Vaccines Key Players Sales have been covered from 5 viewpoints:

    1.    GlaxoSmithKline, Plc
    2.    Merck & Co.
    3.    Sanofi Pasteur’s
    4.    Pfizer, Inc.’s
    5.    CSL Limited


    Report Details:

    Report Features Details
    Base Year 2021
    Historical Period 2016 - 2021
    Forecast Period 2022-2027
    Market US$ Billion
    Segment Covered Disease wise, By Regions, Vaccines
    Regions Covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa
    Companies Covered GlaxoSmithKline, Merck & Co, Sanofi Pasteur's, Pfizer, Inc. and CSL Limited
    Customization Scope 20% Free Customization
    Post-Sale Analyst Support 1 Year (52 Weeks)
    Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on request)

     

    Frequently Asked Questions:

    • What are the growth estimates for global pediatric vaccines market till 2027?
    • What are the key factors driving growth of the global pediatric vaccines market?
    • What are the key factors hampering growth of theglobal pediatric vaccines market?
    • What is the status of disease wisemarket and number inglobal pediatric vaccines market?
    • What will be the growth of Global Pediatric Vaccines Market in the foreseeable future?
    • Who are the key players in the Global Pediatric Vaccines Market?
    • How did the ongoing coronavirus (COVID-19) pandemic impacted the Global Pediatric Vaccines industry growth?

    1.    Introduction

    2.    Research Methodology
    3.    Executive Summary

    4.    Market Dynamics

    4.1    Growth Driver
    4.2    Challenges


    5.    Pediatric (Infant) Vaccines Market
    6.    Pediatric Vaccinated Numbers


    7.    Market & Numbers Share – Pediatric Vaccine Analysis

    7.1    Pediatric Vaccine Market Share
    7.2    Pediatric Vaccinated Population Share
    7.3    By Regions Market share


    8.    Disease wise – Pediatric (Infants) Vaccines Market

    8.1    Influenza
    8.2    MMR (Measles, Mumps, and Rubella Vaccine)
    8.3    Pneumococcal
    8.4    Meningococcal
    8.5    Hepatitis
    8.6    DTaP
    8.7    Haemophilus Influenzae Type B (HIB)
    8.8    Combos (Combination)
    8.9    Polio
    8.10    Rotavirus
    8.11    Varicella


    9.    Disease wise – Numbers of Vaccinated Pediatric (Infants)

    9.1    Influenza
    9.2    MMR
    9.3    Pneumococcal
    9.4    Meningococcal
    9.5    Hepatitis
    9.6    DTaP
    9.7    Hib (Haemophilus Influenzae Type B)
    9.8    Combos (Combination Vaccines)
    9.9    Polio
    9.10    Rotavirus
    9.11    Varicella


    10.    By Region– Pediatric (Infants) Vaccines Market and Number

    10.1    North America

    10.1.1    Market
    10.1.2    Number

    10.2    Europe

    10.2.1    Market
    10.2.2    Number

    10.3    Asia Pacific

    10.3.1    Market
    10.3.2    Number

    10.4    Latin America

    10.4.1    Market
    10.4.2    Number

    10.5    Middle East and Africa

    10.5.1    Market
    10.5.2    Number


    11.    Mergers and Acquisitions in the Vaccine Industry

    12.    Vaccines and Regulator’s Interventions

    12.1    Making and Meeting Standards of Quality and Safety
    12.2    Vaccine Funding


    13.    Vaccines – Products and Pipeline

    13.1    GSK Vaccine Product Pipeline
    13.2    Merck Vaccine Product Pipeline
    13.3    Sanofi Vaccine Product Pipeline
    13.4    Pfizer Vaccine Product Pipeline


    14.    Porters Five Forces

    14.1    Overview
    14.2    Bargaining Power of Buyers
    14.3    Bargaining Power of Suppliers
    14.4    Degree of Competition
    14.5    Threat of New Entrants
    14.6    Threat of Substitutes


    15.    Company Analysis

    15.1    GlaxoSmithKline, plc.

    15.1.1    Overview
    15.1.2    Recent Development
    15.1.3    Sales Analysis

    15.2    Merck & Co.

    15.2.1    Overview
    15.2.2    Recent Development
    15.2.3    Sales Analysis

    15.3    Sanofi Pasteur’s

    15.3.1    Overview
    15.3.2    Recent Development
    15.3.3    Sales Analysis

    15.4    Pfizer, Inc.’s

    15.4.1    Overview
    15.4.2    Recent Development
    15.4.3    Sales Analysis

    15.5    CSL Limited

    15.5.1    Overview
    15.5.2    Recent Development
    15.5.3    Sales Analysis


    List Of Figures:

    Figure-01:        Global Pediatric (Infant) Vaccines Market (Million US$), 2016 – 2021
    Figure-02:        Global – Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2022 – 2027
    Figure-03:        Global – Pediatric (Infant) Vaccines Number (Million), 2016 – 2021
    Figure-04:        Global – Forecast for Pediatric (Infant) Vaccines Number (Million), 2022 – 2027
    Figure-05:        Disease wise – Influenza Market (Million US$), 2016 – 2021
    Figure-06:        Disease wise – Forecast for Influenza Market (Million US$), 2022 – 2027
    Figure-07:        Disease wise – MMR (Measles, Mumps, and Rubella Vaccine) Market (Million US$), 2016 – 2021
    Figure-08:        Disease wise – Forecast for MMR (Measles, Mumps, and Rubella Vaccine) Market (Million US$), 2022 – 2027
    Figure-09:        Disease wise – Pneumococcal Market (Million US$), 2016 – 2021
    Figure-10:        Disease wise – Forecast for Pneumococcal Market (Million US$), 2022 – 2027
    Figure-11:        Disease wise – Meningococcal Market (Million US$), 2016 – 2021
    Figure-12:        Disease wise – Forecast for Meningococcal Market (Million US$), 2022 – 2027
    Figure-13:        Disease wise – Hepatitis Market (Million US$), 2016 – 2021
    Figure-14:        Disease wise – Forecast for Hepatitis Market (Million US$), 2022 – 2027
    Figure-15:        Disease wise – DTaP Market (Million US$), 2016 – 2021
    Figure-16:        Disease wise – Forecast for DTaP Market (Million US$), 2022 – 2027
    Figure-17:        Disease wise – Haemophilus Influenzae Type B (HIB) Market (Million US$), 2016 – 2021
    Figure-18:        Disease wise – Forecast for Haemophilus Influenzae Type B (HIB) Market (Million US$), 2022 – 2027
    Figure-19:        Disease wise – Combos (Combination) Market (Million US$), 2016 – 2021
    Figure-20:        Disease wise – Forecast for Combos (Combination) Market (Million US$), 2022 – 2027
    Figure-21:        Disease wise – Polio Market (Million US$), 2016 – 2021
    Figure-22:        Disease wise – Forecast for Polio Market (Million US$), 2022 – 2027
    Figure-23:        Disease wise – Rotavirus Market (Million US$), 2016 – 2021
    Figure-24:        Disease wise – Forecast for Rotavirus Market (Million US$), 2022 – 2027
    Figure-25:        Disease wise – Varicella Market (Million US$), 2016 – 2021
    Figure-26:        Disease wise – Forecast for Varicella Market (Million US$), 2022 – 2027
    Figure-27:        Disease wise – Influenza Number (Million), 2016 – 2021
    Figure-28:        Disease wise – Forecast for Influenza Number (Million), 2022 – 2027
    Figure-29:        Disease wise – MMR Number (Million), 2016 – 2021
    Figure-30:        Disease wise – Forecast for MMR Number (Million), 2022 – 2027
    Figure-31:        Disease wise – Pneumococcal Number (Million), 2016 – 2021
    Figure-32:        Disease wise – Forecast for Pneumococcal Number (Million), 2022 – 2027
    Figure-33:        Disease wise – Meningococcal Number (Million), 2016 – 2021
    Figure-34:        Disease wise – Forecast for Meningococcal Number (Million), 2022 – 2027
    Figure-35:        Disease wise – Hepatitis Number (Million), 2016 – 2021
    Figure-36:        Disease wise – Forecast for Hepatitis Number (Million), 2022 – 2027
    Figure-37:        Disease wise – DTaP Number (Million), 2016 – 2021
    Figure-38:        Disease wise – Forecast for DTaP Number (Million), 2022 – 2027
    Figure-39:        Disease wise – Hib (Haemophilus Influenzae Type B) Number (Million), 2016 – 2021
    Figure-40:        Disease wise – Forecast for Hib (Haemophilus Influenzae Type B) Number (Million), 2022 – 2027
    Figure-41:        Disease wise – Combos (Combination Vaccines) Number (Million), 2016 – 2021
    Figure-42:        Disease wise – Forecast for Combos (Combination Vaccines) Number (Million), 2022 – 2027
    Figure-43:        Disease wise – Polio Number (Million), 2016 – 2021
    Figure-44:        Disease wise – Forecast for Polio Number (Million), 2022 – 2027
    Figure-45:        Disease wise – Rotavirus Number (Million), 2016 – 2021
    Figure-46:        Disease wise – Forecast for Rotavirus Number (Million), 2022 – 2027
    Figure-47:        Disease wise – Varicella Number (Million), 2016 – 2021
    Figure-48:        Disease wise – Forecast for Varicella Number (Million), 2022 – 2027
    Figure-49:        GlaxoSmithKline, plc.’s Vaccines Sales – Global Revenue (Million US$), 2016 – 2021
    Figure-50:        GlaxoSmithKline, plc.’s Vaccines Sales – Forecast for Global Revenue (Million US$), 2022 – 2027
    Figure-51:         Merck & Co. Vaccines Sales – Global Revenue (Million US$), 2016 – 2021
    Figure-52:        Merck & Co. Vaccines Sales – Forecast for Global Revenue (Million US$), 2022 – 2027
    Figure-53:        Sanofi Pasteur’s Vaccines Sales – Global Revenue (Million US$), 2016 – 2021
    Figure-54:        Sanofi Pasteur’s Vaccines Sales – Forecast for Global Revenue (Million US$), 2022 – 2027
    Figure-55:        Pfizer, Inc.’s Vaccines Sales – Global Revenue (Million US$), 2016 – 2021
    Figure-56:        Pfizer, Inc.’s Vaccines Sales – Forecast for Global Revenue (Million US$), 2022 – 2027
    Figure-57:        Thoracic Aortic Aneurysm (TAA)CSL Limited sales – Global Revenue (Million US$), 2016 – 2021
    Figure-58:        Thoracic Aortic Aneurysm (TAA)CSL Limited sales – Forecast for Global Revenue (Million US$), 2022 – 2027


    List Of Tables:

    Table-01:        Global – Pediatric Vaccines Market Share (Percent), 2016 – 2021
    Table-02:        Global – Forecast for Pediatric Vaccines Market Share (Percent), 2022 – 2027
    Table-03:        Global – Pediatric Vaccines Population Share (Percent), 2016 – 2021
    Table-04:        Global – Forecast for Pediatric Vaccines Population Share (Percent), 2022 – 2027

    • Description
      Price
    • Chapter 1, 2, 3 & 4     Pages : 9
      $500
    • Chapter 5 & 6     Pages : 6
      $900
    • Chapter 7     Pages : 10
      $900
    • Chapter 8     Pages : 35
      $800
    • Chapter 9     Pages : 35
      $800
    • Chapter 10.1     Pages : 6
      $300
    • Chapter 10.2     Pages : 6
      $300
    • Chapter 10.3     Pages : 6
      $300
    • Chapter 10.4     Pages : 6
      $300
    • Chapter 10.5     Pages : 6
      $300
    • Chapter 11     Pages : 2
      $200
    • Chapter 12     Pages : 6
      $500
    • Chapter 13     Pages : 14
      $600
    • Chapter 14     Pages : 6
      $400
    • Chapter 15.1     Pages : 5
      $150
    • Chapter 15.2     Pages : 5
      $150
    • Chapter 15.3     Pages : 5
      $150
    • Chapter 15.4     Pages : 5
      $150
    • Chapter 15.5     Pages : 5
      $150

    Related Reports